H Hussein1,2, F Zaccardi2, K Khunti2, S Seidu2, M J Davies2, L J Gray1. 1. Department of Health Sciences, University of Leicester, Leicester, UK. 2. Leicester Diabetes Centre, Leicester General Hospital, Leicester, UK.
Abstract
AIMS: To compare the cardiovascular efficacy and safety of sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in adults with Type 2 diabetes. METHODS: Electronic databases were searched from inception to 22 October 2018 for randomized controlled trials designed to assess the cardiovascular efficacy of SGLT2 inhibitors or GLP-1RAs with regard to a three-point composite measure of major adverse cardiovascular events (non-fatal stroke, non-fatal myocardial infarction and cardiovascular mortality). Cardiovascular and safety data were synthesized using Bayesian network meta-analyses. RESULTS: Eight trials, including 60 082 participants, were deemed eligible for the network meta-analysis. Both SGLT2 inhibitors [hazard ratio 0.86 (95% credible interval 0.74, 1.01]) and GLP-1RAs [hazard ratio 0.88 (95% credible interval 0.78, 0.98)] reduced the three-point composite measure compared to placebo, with no evidence of differences between them [GLP-1RAs vs SGLT2 inhibitors: hazard ratio 1.02 (95% credible interval 0.83, 1.23)]. SGLT2 inhibitors reduced risk of hospital admission for heart failure compared to placebo [hazard ratio 0.67 (95% credible interval 0.53, 0.85)] and GLP-1RAs [hazard ratio 0.71 (95% credible interval 0.53, 0.93)]. No differences were found between the two drug classes in non-fatal stroke, non-fatal myocardial infarction, cardiovascular mortality, all-cause mortality or safety outcomes. CONCLUSIONS: SGLT2 inhibitors and GLP-1RAs reduced the three-point major adverse cardiovascular event risk compared to placebo, with no differences between them. Compared with GLP-1RAs and placebo, SGLT2 inhibitors led to a larger reduction in hospital admission for heart failure risk.
AIMS: To compare the cardiovascular efficacy and safety of sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in adults with Type 2 diabetes. METHODS: Electronic databases were searched from inception to 22 October 2018 for randomized controlled trials designed to assess the cardiovascular efficacy of SGLT2 inhibitors or GLP-1RAs with regard to a three-point composite measure of major adverse cardiovascular events (non-fatal stroke, non-fatal myocardial infarction and cardiovascular mortality). Cardiovascular and safety data were synthesized using Bayesian network meta-analyses. RESULTS: Eight trials, including 60 082 participants, were deemed eligible for the network meta-analysis. Both SGLT2 inhibitors [hazard ratio 0.86 (95% credible interval 0.74, 1.01]) and GLP-1RAs [hazard ratio 0.88 (95% credible interval 0.78, 0.98)] reduced the three-point composite measure compared to placebo, with no evidence of differences between them [GLP-1RAs vs SGLT2 inhibitors: hazard ratio 1.02 (95% credible interval 0.83, 1.23)]. SGLT2 inhibitors reduced risk of hospital admission for heart failure compared to placebo [hazard ratio 0.67 (95% credible interval 0.53, 0.85)] and GLP-1RAs [hazard ratio 0.71 (95% credible interval 0.53, 0.93)]. No differences were found between the two drug classes in non-fatal stroke, non-fatal myocardial infarction, cardiovascular mortality, all-cause mortality or safety outcomes. CONCLUSIONS:SGLT2 inhibitors and GLP-1RAs reduced the three-point major adverse cardiovascular event risk compared to placebo, with no differences between them. Compared with GLP-1RAs and placebo, SGLT2 inhibitors led to a larger reduction in hospital admission for heart failure risk.
Authors: Jason T Alexander; Erin M Staab; Wen Wan; Melissa Franco; Alexandra Knitter; M Reza Skandari; Shari Bolen; Nisa M Maruthur; Elbert S Huang; Louis H Philipson; Aaron N Winn; Celeste C Thomas; Meltem Zeytinoglu; Valerie G Press; Elizabeth L Tung; Kathryn Gunter; Brittany Bindon; Sanjay Jumani; Neda Laiteerapong Journal: J Gen Intern Med Date: 2021-11-30 Impact factor: 6.473
Authors: Osamah M Alfayez; Omar A Almohammed; Omar S Alkhezi; Abdulaali R Almutairi; Majed S Al Yami Journal: Cardiovasc Diabetol Date: 2020-06-22 Impact factor: 9.951
Authors: Lindsay E Clegg; Robert C Penland; Srinivas Bachina; David W Boulton; Marcus Thuresson; Hiddo J L Heerspink; Stephanie Gustavson; C David Sjöström; James A Ruggles; Adrian F Hernandez; John B Buse; Robert J Mentz; Rury R Holman Journal: Cardiovasc Diabetol Date: 2019-10-22 Impact factor: 9.951
Authors: Suetonia C Palmer; Britta Tendal; Reem A Mustafa; Per Olav Vandvik; Sheyu Li; Qiukui Hao; David Tunnicliffe; Marinella Ruospo; Patrizia Natale; Valeria Saglimbene; Antonio Nicolucci; David W Johnson; Marcello Tonelli; Maria Chiara Rossi; Sunil V Badve; Yeoungjee Cho; Annie-Claire Nadeau-Fredette; Michael Burke; Labib I Faruque; Anita Lloyd; Nasreen Ahmad; Yuanchen Liu; Sophanny Tiv; Tanya Millard; Lucia Gagliardi; Nithin Kolanu; Rahul D Barmanray; Rita McMorrow; Ana Karina Raygoza Cortez; Heath White; Xiangyang Chen; Xu Zhou; Jiali Liu; Andrea Flores Rodríguez; Alejandro Díaz González-Colmenero; Yang Wang; Ling Li; Surya Sutanto; Ricardo Cesar Solis; Fernando Díaz González-Colmenero; René Rodriguez-Gutierrez; Michael Walsh; Gordon Guyatt; Giovanni F M Strippoli Journal: BMJ Date: 2021-01-13
Authors: Marco Trevisan; Edouard L Fu; Karolina Szummer; Anna Norhammar; Pia Lundman; Christoph Wanner; Arvid Sjölander; Tomas Jernberg; Juan Jesus Carrero Journal: Eur Heart J Cardiovasc Pharmacother Date: 2021-03-15
Authors: Jennifer E Nyland; Nazia T Raja-Khan; Kerstin Bettermann; Philippe A Haouzi; Douglas L Leslie; Jennifer L Kraschnewski; Leslie J Parent; Patricia Sue Grigson Journal: Diabetes Date: 2021-09-27 Impact factor: 9.461